Gain Therapeutics, Inc. (GANX)

Gain Therapeutics' stock price has been volatile over the past six months, with a 52-week range between $1.41 and $4.34. The stock has underperformed the broader US market and the US Biotechs industry over the past year. The company's cash reserves significantly increased, reaching $20.8 million as of December 31, 2025. In March 2026, the company announced promising results from its Phase 1b study of GT-02287 for Parkinson's disease and plans to begin a Phase 2 clinical trial in Q3 2026.

There is no explicit information available regarding demand seasonality for Gain Therapeutics' products and services. Demand is primarily driven by clinical trial outcomes, regulatory approvals, and the prevalence of the diseases it aims to treat, rather than seasonal patterns.

Gain Therapeutics operates in the Healthcare sector, focusing on Biotechnology, Drug Discovery, and Pharmaceutical Preparation Manufacturing. Their primary product candidate, GT-02287, is in clinical development for Parkinson's disease. The company is also developing preclinical assets for lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology.

Gain Therapeutics is headquartered in Bethesda, Maryland, United States. The company's operations extend to Switzerland, Spain, the United States, and Australia.

Gain Therapeutics' brand reputation appears generally positive within the analyst community, driven by the progress of its clinical programs. The company has received a consensus rating of "Moderate Buy" from analysts. Positive analyst updates have been noted, particularly in response to promising clinical data for GT-02287 in Parkinson's disease.

Gain Therapeutics has a significant institutional ownership presence, with 50 institutional owners and shareholders holding 8,062,760 shares as of March 26, 2026. Institutional ownership stands at 20.99%, while insider ownership is at 1.13%.